pharmaceuticals

pharmaceuticals Articles

Arrowhead Pharmaceuticals shares made a considerable gain early on Thursday after the firm announced data from its hepatitis B clinical trial with ARO-HBV.
Clinical-stage biopharmaceutical company Principia Biopharma has amended its filing with the SEC for its initial public offering.
BioCryst Pharmaceuticals shares fell on Tuesday after the company announced initial results from its hereditary angioedema trial.
Clinical-stage drug maker Sutro Biopharma has filed with the SEC regarding its initial public offering.
InsysTherapeutics shares made a handy gain early on Thursday after the company announced an update from the FDA.
Akcea and Ionis were each crushed on Tuesday after the firms announced that they received a Complete Response Letter from the FDA.
Pfizer shares slipped on Monday despite the company posting positive results from a late-stage tafamidis trial.
The August 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks was mixed.
Kala Pharmaceuticals shares dipped on Thursday after the U.S. Food and Drug Administration (FDA) announced that it had approved INVELTYS (loteprednol etabonate ophthalmic suspension) 1% for the...
Big Pharma is looking good for investors in the second half of 2018. That's the message from the research team at Bank of America Merrill Lynch.
Amneal Pharma shares hit a post-IPO high in Monday’s session after the company announced a new licensing and supply agreement.
24/7 Wall St. has identified several biotech analyst calls from Wall Street wherein the analysts are projecting upside of 100% to about 400%.
Mylan has had a stranglehold on the market for EpiPen, but this is all changing after the FDA approved Teva for a generic version of it.
Teva and Regeneron both saw handy gains on Thursday after the companies posted positive topline results from their late-stage trial of fasinumab in patients with chronic pain from osteoarthritis...
Vertex Pharmaceuticals shares saw a handy gain on Thursday after the FDA gave a nod to Vertex’s cystic fibrosis treatment.